RE: Long press release! Looks OK for once22 Oct 2025 17:21
The factual headline numbers (from the RNS)
• New equity financing: subscription of 161,061,510 new ordinary shares at 7 pence = ≈£11.3m (before costs). 
• March 2025 tranche: final tranche of 138,977,614 new ordinary shares at 7p expected imminently (so the March fundraise is not yet fully in the register). 
• Conditional off-market buyback: up to 143,565,582 existing ordinary shares at 7 pence per share (to be acquired before 31 March 2026, subject to shareholder approvals). 
• Warrants to be cancelled: warrants over 101,113,992 ordinary shares (these were valued by the company and are to be acquired and cancelled). 
• Other numbers in the RNS: 9M 2025 revenues US$185.2m, cash US$101.8m, net debt US$629.9m, trade receivables US$493.3m. 
⸻
Share count / dilution — step-by-step (my arithmetic and assumptions)
Base share count used (company disclosure): 1,610,615,111 ordinary shares in issue at 26 June 2025. (This is stated in the company filings referenced in the RNS). 
Savannah’s announcement refers to:
• March tranche = 138,977,614 shares (expected imminently). 
• New financing = 161,061,510 shares. 
Pro-forma “enlarged share capital” (if both the March tranche and the new financing are issued):
1,610,615,111 + 138,977,614 + 161,061,510 = 1,910,654,235 shares. (this is the denominator I use for the “enlarged” numbers below). 
NIPCO stated position: the RNS says NIPCO (the new investor) intends a total investment of ≈£28.7m, composed of:
• the primary subscription (the 161,061,510 new shares at 7p = ~£11.3m) and secondary purchases of existing shares (113,378,685 shares from the March fundraising stock and ~135,674,944 shares bought on the secondary market). The RNS says that, on a pro-forma basis, NIPCO would hold around 19.4% of the enlarged capital. 
My straight arithmetic (shares acquired by NIPCO / enlarged shares):
NIPCO total shares acquired (per RNS components) = 161,061,510 + 113,378,685 + 135,674,944 = 410,115,139 shares.
410,115,139 / 1,910,654,235 = ≈21.46% (this simple division returns ≈21.5%).
→ Why that differs from the RNS 19.4% number: the company’s “pro-forma” percentage (19.4%) reflects other simultaneous transactions (director buys, EBT sales, or other secondary trades) and how the company defines the “enlarged capital” in the detailed pro-forma table. the RNS text bundles several primary and secondary transactions; the company’s pro-forma denominator likely includes further adjustments I don’t have exact line-by-line here. The important point: the stated company figure is ~19.4%; my raw shares/math using only the headline items gives ~21.5%, so small differences in which share flows are included matter. (See RNS for the company’s pro-forma calculation). 
⸻